Content about clopidogrel bisulfate

December 26, 2013

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years.

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years. But according to IMS’ latest figures, it was not the start of a trend.

November 27, 2012

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

May 17, 2012

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

March 9, 2012

A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

RALEIGH, N.C. — A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

Kerr Drug announced Friday that it would work with the University of North Carolina Chapel Hill's Eshelman School of Pharmacy to explore the feasibility of a program for Sanofi's and Bristol-Myers Squibb's blood-thinning drug Plavix (clopidogrel bisulfate).

February 11, 2010

Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as...

WHAT IT MEANS AND WHY ITS IMPORTANT Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as CVS and Walgreens, as blockbuster drugs like Pfizer’s Lipitor (atorvastatin) and Sanofi-Aventis’ and Bristol-Myers Squibb’s Plavix (clopidogrel bisulfate) come off patent and face generic competition, but they would do well to remember an important factor: the patent cliff.